T
Tethis
Biotech & Life Sciences · Milan, Italy · Founded 2004
Automated pre-analytical platform for comprehensive liquid biopsy MoreLess
Tethis S.p.A. is a biotechnology company, founded in 2004 by Massimo Gatelli and Paolo Milani, headquartered in Milan, Italy. The company is focused on improving the reliability and scalability of in-vitro diagnostics by applying bio and nanotechnology. Tethis has developed an innovative workflow to integrate liquid biopsy into clinical practice for precise cancer management.
The company's core technology consists of the See.d® instrument and proprietary nanocoated SmartBioSurface® (SBS) slides. The See.d® platform is a fully automated, universal blood sample preparator that processes blood at the point of collection. It automates the separation of plasma, lysis of red blood cells, and fixes white blood cells onto the specialized SBS slides, while also making plasma available for cell-free content analysis. This process standardizes the pre-analytical steps, a critical bottleneck in liquid biopsy, ensuring maximum sample integrity and quality for downstream multiomic analysis. The nanocoated slides allow for the identification and characterization of rare cells, like circulating tumor cells (CTCs), with high sensitivity, even in early-stage cancers.
Tethis serves hospitals, diagnostic laboratories, and research institutions. Its business model is based on selling the See.d® hardware systems and the consumable SmartBioSurface® slides. The company has engaged in multiple collaborations to advance its technology, including a research agreement with Sheba Medical Center in Israel to evaluate CTCs in rectal cancer and with the European Institute of Oncology in Milan for a clinical study on the See.d platform's performance. Tethis has secured significant funding to support its development, including a €15 million investment in January 2025 from the Enea TECH and Biomedical Foundation and a prior investment from Indaco Ventures and Genextra.
Keywords: liquid biopsy, cancer diagnostics, in-vitro diagnostics, nanotechnology, pre-analytical platform, circulating tumor cells, See.d instrument, SmartBioSurface, oncology, automated sample preparation, molecular diagnostics, medical devices, digital pathology, precision medicine, cancer monitoring, biomarker discovery, cell analysis, multiomics, cfDNA, CTC detection
Company overview
Tethis company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2004
- Headquarters
- Milan, Italy
- Employees
- 36
- Open positions
- None listed
- Dealroom signal
- 87.6
Valuation & funding
Tethis funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Feb 2025 | $17M | $66M | Fondazione ENEA Tech | ↗ |
| GRANT✓Other financing | Mar 2018 | $55K | — | European Innovation Council | — |
| SUPPORT PROGRAM✓Other financing | Jan 2018 | $0 | — | EIT Health | — |
| EARLY VC✓Equity / VC | Feb 2014 | — | — | Undisclosed | — |
| EARLY VC✓Equity / VC | Feb 2013 | — | — | Undisclosed | — |
| EARLY VC✓Equity / VC | Sep 2012 | Undisclosed | — | ||
| EARLY VC✓Equity / VC | Feb 2012 | Undisclosed | — | ||
| EARLY VC✓Equity / VC | Dec 2011 | Undisclosed | — | ||
| GRANT✓Other financing | Apr 2011 | Undisclosed | — | ||
| EARLY VC✓Equity / VC | May 2010 | Undisclosed | — |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
Growth signals
Tethis website traffic
Latest recorded traffic for Tethis is 330 monthly website visits, up 13.8% over the last three months. Tethis's team grew 12.5% over the past year.
Comparisons
Tethis compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Tethis's talent
Source: Dealroom Talent Intelligence.
Investors
6 investors on Tethis's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where Tethis has talent and traffic
team presence
In the news
Latest news about Tethis
Recent press, funding announcements, and product moves mentioning Tethis — open to read from the original sources.
Market sentiment
What the market is saying about Tethis
An AI-synthesized read of the highest-engagement posts about Tethis on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Tethis’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.